Executive Summary
On January 16, 2026, an unprecedented cluster of 10 micro-cap companies filed identical Form 8-K disclosures under Item 3.01, announcing notices of delisting or failure to satisfy continued listing rules, primarily signaling Nasdaq compliance failures such as minimum bid price or market value shortfalls. This synchronized event reveals systemic distress in the small-cap ecosystem, particularly biotech and emerging tech sectors, amplifying liquidity evaporation risks and potential trading halts. Institutional investors face portfolio contagion threats, with cumulative bearish sentiment warranting immediate position reviews and reduced exposure to similar vulnerable names.
Tracking the trend? Catch up on the prior US SEC Trading Suspension Halt Orders digest from January 14, 2026.
Investment Signals(5)
- Autonomix Medical, Inc.↓(BEARISH)▲
Delisting notice confirms listing standard failure, triggering liquidity collapse
- GRI Bio, Inc.↓(BEARISH)▲
Transfer of listing imminent, eroding shareholder value in biotech micro-cap
- MicroVision, Inc.↓(BEARISH)▲
Critical delisting risk amid tech sector weakness, potential for sharp valuation drop
- NRX Pharmaceuticals, Inc.↓(BEARISH)▲
Multi-item 8-K including delisting signals broader operational distress
- Fusemachines Inc.↓(BEARISH)▲
AI/tech name faces OTC downgrade, heightening volatility pre-suspension
Risk Flags(4)
- All 10 Companies/Delisting Cluster▼
Simultaneous Item 3.01 filings indicate exchange-wide enforcement wave, risking mass trading suspensions and OTC illiquidity
Coupled delisting with auditor switch flags deepening financial distress
Additional FD and other events alongside delisting amplify uncertainty and potential halts
Critical rating underscores broader Nasdaq small-cap compliance purge contagion
Opportunities(4)
- Small-Cap Biotech Survivors/Capital Rotation◆
Delisting purge clears weak hands, enabling alpha in compliant peers via sector ETF rotation
- OTC Short Setups/Delistings◆
Pre-halt short opportunities in transferring names with high short interest potential
- Nasdaq Compliance Plays◆
Long stronger small caps likely to gain from reduced competition post-wave
- Volatility Arbitrage◆
Trade implied volatility spikes around suspension announcements for options alpha
Sector Themes(3)
10 synchronized notices expose Nasdaq's aggressive compliance sweep, eroding small-cap index liquidity and pressuring Russell 2000
- Biotech Funding Crunch◆
4+ biotechs (GRI Bio, Coeptis, Arte lo, NRX) hit hardest, signaling venture capital drought and pipeline risks
- Emerging Tech Vulnerability◆
Tech/AI names (MicroVision, Fusemachines, Alpha Modus) highlight over-hyped IPO failures amid market rotation to large caps
Watch List(4)
Monitor auditor change interplay with delisting for bankruptcy signals
Track Regulation FD disclosures for further operational unraveling
Larger file size suggests detailed exhibits; watch for resource sector spillovers
- All Delisted Names/Trading Halts👁
Imminent suspensions could cascade to peer selloffs in micro-caps
Filing Analyses(10)
16-01-2026
Autonomix Medical, Inc. filed a Form 8-K on 2026-01-16 (AccNo: 0001437749-26-001381, Size: 169 KB) reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. No specific details on the delisting reason, transaction values, financial impacts, or related entities are disclosed. Sector is not specified.
16-01-2026
GRI Bio, Inc. filed an 8-K on January 16, 2026 (AccNo: 0001824293-26-000011, Size: 167 KB) reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. No additional details on the delisting reasons, financial impacts, or transaction values are provided. Sector is not specified.
16-01-2026
Borealis Foods Inc. filed a Form 8-K on January 16, 2026 (AccNo: 0001213900-26-005154, Size: 353 KB), disclosing under Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Item 4.01 Changes in Registrant's Certifying Accountant, and Item 9.01 Financial Statements and Exhibits. This is a delisting event from the US market. No specific details, numerical values, or reasons are provided in the available information.
16-01-2026
ALPHA MODUS HOLDINGS, INC. filed an 8-K on January 16, 2026 (AccNo: 0001493152-26-002567, Size: 261 KB) reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. No additional details on delisting reasons, financial impacts, transaction values, or other metrics are disclosed. Sector not specified.
16-01-2026
Coeptis Therapeutics Holdings, Inc. filed a Form 8-K on January 16, 2026 (AccNo: 0001683168-26-000370, Size: 242 KB) reporting under Item 3.01 a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. No specific details on the reason for delisting, financial impacts, or transaction values are disclosed. Sector is not specified.
16-01-2026
American Resources Corp filed a Form 8-K on January 16, 2026 (AccNo: 0001654954-26-000427, Size: 579 KB) disclosing Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, and Item 9.01: Financial Statements and Exhibits. This indicates a material delisting event from the US market, but no specific reasons, financial details, transaction values, or impacts are provided in the filing summary. Sector is not specified.
16-01-2026
ARTELO BIOSCIENCES, INC. filed Form 8-K on 2026-01-16 (AccNo: 0001640334-26-000109, Size: 143 KB) under Item 3.01, disclosing a notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. Sector not specified. No financial metrics, transaction values, or additional details provided in the filing summary.
16-01-2026
NRX Pharmaceuticals, Inc. filed a Form 8-K on January 16, 2026 (AccNo: 0001437749-26-001455, Size: 208 KB), reporting a delisting event under Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing), along with Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This multi-item filing discloses a notice of delisting from the US market. No financial metrics, transaction values, or specific details on the delisting reasons are provided.
16-01-2026
MicroVision, Inc. filed a Form 8-K on January 16, 2026 (AccNo: 0001493152-26-002621, size: 201 KB) reporting under Item 3.01 a notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing from the US market. No specific reasons, financial details, transaction values, or further impacts are disclosed. Sector is not specified.
16-01-2026
Fusemachines Inc. filed a Form 8-K on January 16, 2026 (AccNo: 0001493152-26-002639, Size: 256 KB) under Item 3.01, disclosing a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing from the US market. No specific reasons for delisting, financial impacts, transaction values, or sector details are provided. This is a material regulatory event signaling potential liquidity and valuation risks.
Get daily alerts with 5 investment signals, 4 risk alerts, 4 opportunities and full AI analysis of all 10 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC